• Je něco špatně v tomto záznamu ?

Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

R. Aggarwal, J. Schessl, C. Charles-Schoeman, Z. Bata-Csörgő, MM. Dimachkie, Z. Griger, S. Moiseev, CV. Oddis, E. Schiopu, J. Vencovský, I. Beckmann, E. Clodi, T. Levine, ProDERM investigators

. 2024 ; 26 (1) : 27. [pub] 20240117

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007562

BACKGROUND: Dermatomyositis is an idiopathic inflammatory myopathy characterised by rashes and progressive muscle weakness. The recent ProDERM (Progress in DERMatomyositis) study is the first large randomised, placebo-controlled trial to establish the efficacy and safety of intravenous immunoglobulin (IVIg) in adult patients with dermatomyositis. Objectives of this analysis were to closely examine the safety and tolerability of IVIg in patients from the ProDERM study. METHODS: ProDERM was a double-blind, randomised, placebo-controlled, multicentre, phase 3 study. In the first period (weeks 0-16), adults with active dermatomyositis received 2.0 g/kg IVIg (Octagam 10%; Octapharma AG) or placebo every 4 weeks. In the open-label extension period (weeks 16-40), all patients received IVIg for 6 additional cycles; dose reduction (1.0 g/kg) was permitted if patients were stable. Treatment-emergent adverse events (TEAEs) were documented. RESULTS: The 95 patients enrolled were randomised to receive IVIg (N = 47) or placebo (N = 48) in the first period, with 5 switching from placebo to IVIg. Overall, 664 IVIg infusion cycles were administered. During the first period, 113 TEAEs were possibly/probably related to treatment in 30/52 patients (57.7%) receiving IVIg and 38 in 11 patients (22.9%) on placebo. Eight patients discontinued therapy due to IVIg-related TEAEs. Eight thromboembolic events (TEEs) occurred in six patients on IVIg; six in five patients were deemed possibly/probably related to IVIg. Patients with TEEs exhibited more baseline TEE risk factors than those without TEEs (2.4-15.2-fold higher). Lowering infusion rate reduced the rate of TEEs, and none occurred at the lower IVIg dose. No haemolytic transfusion reactions or deaths occurred. CONCLUSIONS: Results from this study demonstrate that IVIg has a favourable safety profile for treatment of adult dermatomyositis patients and provides evidence that will help to inform treatment choice for these patients. Dermatomyositis patients receiving high-dose IVIg should be monitored for TEEs, and a low rate of infusion should be used to minimise TEE risk, particularly in those with pre-existing risk factors. TRIAL REGISTRATION: ProDERM study (NCT02728752).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007562
003      
CZ-PrNML
005      
20240423160053.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-023-03232-2 $2 doi
035    __
$a (PubMed)38233885
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aggarwal, Rohit $u Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. aggarwalr@upmc.edu
245    10
$a Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study / $c R. Aggarwal, J. Schessl, C. Charles-Schoeman, Z. Bata-Csörgő, MM. Dimachkie, Z. Griger, S. Moiseev, CV. Oddis, E. Schiopu, J. Vencovský, I. Beckmann, E. Clodi, T. Levine, ProDERM investigators
520    9_
$a BACKGROUND: Dermatomyositis is an idiopathic inflammatory myopathy characterised by rashes and progressive muscle weakness. The recent ProDERM (Progress in DERMatomyositis) study is the first large randomised, placebo-controlled trial to establish the efficacy and safety of intravenous immunoglobulin (IVIg) in adult patients with dermatomyositis. Objectives of this analysis were to closely examine the safety and tolerability of IVIg in patients from the ProDERM study. METHODS: ProDERM was a double-blind, randomised, placebo-controlled, multicentre, phase 3 study. In the first period (weeks 0-16), adults with active dermatomyositis received 2.0 g/kg IVIg (Octagam 10%; Octapharma AG) or placebo every 4 weeks. In the open-label extension period (weeks 16-40), all patients received IVIg for 6 additional cycles; dose reduction (1.0 g/kg) was permitted if patients were stable. Treatment-emergent adverse events (TEAEs) were documented. RESULTS: The 95 patients enrolled were randomised to receive IVIg (N = 47) or placebo (N = 48) in the first period, with 5 switching from placebo to IVIg. Overall, 664 IVIg infusion cycles were administered. During the first period, 113 TEAEs were possibly/probably related to treatment in 30/52 patients (57.7%) receiving IVIg and 38 in 11 patients (22.9%) on placebo. Eight patients discontinued therapy due to IVIg-related TEAEs. Eight thromboembolic events (TEEs) occurred in six patients on IVIg; six in five patients were deemed possibly/probably related to IVIg. Patients with TEEs exhibited more baseline TEE risk factors than those without TEEs (2.4-15.2-fold higher). Lowering infusion rate reduced the rate of TEEs, and none occurred at the lower IVIg dose. No haemolytic transfusion reactions or deaths occurred. CONCLUSIONS: Results from this study demonstrate that IVIg has a favourable safety profile for treatment of adult dermatomyositis patients and provides evidence that will help to inform treatment choice for these patients. Dermatomyositis patients receiving high-dose IVIg should be monitored for TEEs, and a low rate of infusion should be used to minimise TEE risk, particularly in those with pre-existing risk factors. TRIAL REGISTRATION: ProDERM study (NCT02728752).
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní imunoglobuliny $x škodlivé účinky $7 D016756
650    12
$a dermatomyozitida $x farmakoterapie $7 D003882
650    _2
$a intravenózní infuze $7 D007262
650    12
$a myozitida $x chemicky indukované $7 D009220
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a výsledek terapie $7 D016896
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schessl, Joachim $u Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany
700    1_
$a Charles-Schoeman, Christina $u University of California, Los Angeles, CA, USA
700    1_
$a Bata-Csörgő, Zsuzsanna $u Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
700    1_
$a Dimachkie, Mazen M $u Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA
700    1_
$a Griger, Zoltan $u Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Moiseev, Sergey $u Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Oddis, Chester V $u Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
700    1_
$a Schiopu, Elena $u Division of Rheumatology, Medical College of Georgia at Augusta University, Augusta, GA, USA
700    1_
$a Vencovský, Jiri $u Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a Beckmann, Irene $u Octapharma Pharmazeutika Produktionsges. m.b.H., Vienna, Austria
700    1_
$a Clodi, Elisabeth $u Octapharma Pharmazeutika Produktionsges. m.b.H., Vienna, Austria
700    1_
$a Levine, Todd $u Phoenix Neurological Associates, Ltd, Phoenix, AZ, USA
710    2_
$a ProDERM investigators
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 26, č. 1 (2024), s. 27
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38233885 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160049 $b ABA008
999    __
$a ok $b bmc $g 2081514 $s 1217329
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 1 $d 27 $e 20240117 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace